NASDAQ:ELDN

Eledon Pharmaceuticals Q2 2026 Earnings Results & Report

Eledon Pharmaceuticals logo
$1.78 -0.12 (-6.32%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.79 +0.01 (+0.73%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eledon Pharmaceuticals missed analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.27 versus the -$0.1580 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.1580
Beat/Miss
Missed by -$0.1120
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Q2 2026 Earnings FAQ

Eledon Pharmaceuticals (NASDAQ:ELDN) reported earnings of -$0.27 per share for Q2 2026, missing the consensus estimate of -$0.1580. The report was announced on Thursday, August 13, 2026.

Eledon Pharmaceuticals Earnings Headlines

What is Noble Financial's Estimate for ELDN FY2026 Earnings?
Eledon Pharmaceuticals (NASDAQ:ELDN) Raised to Sell at Wall Street Zen
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS).

Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS. The therapy is experimental and has not been approved for commercial use.

Eledon is headquartered in Irvine, California. The company’s work is focused on research and clinical development; it does not currently offer an approved commercial product.

View Eledon Pharmaceuticals Profile